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Background: Warfarin prescribing patterns for hemodialysis patients with atrial fibrillation vary widely amongst
nephrologists. This may be due to a paucity of guiding evidence, but also due to concerns of increased risks of
warfarin use in this population. The literature lacks clarity on the balance of warfarin therapy between prevention of
thrombotic strokes and the increased risks of bleeding in hemodialysis patients with atrial fibrillation.
Methods: We performed a survey of Canadian Nephrologists, assessing warfarin prescribing practice, and measured
the certainty in making these choices.
Results: Respondents were consistently uncertain about warfarin use for atrial fibrillation. This uncertainty increased
with a history of falls or starting hemodialysis, even when a high CHADS2 or CHA2DS2VASc score was present. The
majority of respondents agreed that clinical equipoise existed about the use of oral anticoagulation in hemodialysis
patients with atrial fibrillation (72.2%) and that the results of a randomized controlled trial would be relevant to
their practice (98.2%).
Conclusions: A randomized controlled trial of warfarin use in hemodialysis patients with atrial fibrillation would
clarify the risks and benefits of warfarin use in this population.
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Warfarin is indicated in the general population for the
treatment of venous thromboembolism (VTE) and for
prophylaxis of stroke in patients with atrial fibrillation.
A recent non-randomized retrospective database analysis
confirmed that in patients with non-valvular atrial fibril-
lation and chronic kidney disease, the use of warfarin or
aspirin reduced stroke but increased risk of bleeding [1].
However, in patients on dialysis, warfarin is widely used
for nonvalvular atrial fibrillation, though the ratio of
risks to benefits remains unclear [2-6]. Warfarin has not
been studied in randomized trials in this population, and
trials of low-intensity warfarin for the maintenance of
access patency showed no benefit [7,8].* Correspondence: Louise.moist@lhsc.on.ca
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reproduction in any medium, provided the orThe prevalence of atrial fibrillation in patients with end-
stage kidney disease on hemodialysis is higher than that in
the general population, ranging from 7 to 27% [9-12]. In
the United States, the prevalence has tripled from 1992 to
2006. These patients have increased risks for adverse ef-
fects from warfarin: major bleeding including hemorrhagic
stroke [2,13-15], acceleration of vascular calcification, cal-
cific uremic arteriolopathy and warfarin-induced skin ne-
crosis [16-18]. Patients with severe kidney disease were
excluded in the generation and validation of stroke and
bleeding risk calculator scores such as CHADS2 and
CHA2DS2VASc [19-22], which further raises uncertainty
about whether evidence from the general population can
be generalized to people on dialysis.
Internationally, warfarin prescribing patterns for hemo-
dialysis patients with atrial fibrillation vary widely, from
2% in Germany to as high as 37% in Canada [6]. Since
Canadian nephrologists prescribe warfarin frequently in
this situation, the objective of our study was to identify the
degree of uncertainty and clinical equipoise in thesetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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domized trial.
Methods
National survey of nephrologists
We developed a survey consisting of six clinically-
relevant cases, followed by four questions. The cases
were designed to include different standardized CHADS2
and CHA2DS2VASc ischemic stroke risk scores, and vari-
able bleeding risk, and were reviewed independently by
three nephrologists for clinical validity. The additional
questions explicitly evaluated respondents’ sense of clin-
ical equipoise, their willingness to enter patients with
atrial fibrillation into a randomized controlled trial, and
their perceived utility of a randomized control trial of
anticoagulation of hemodialysis patients with atrial fib-
rillation. Respondents were also asked 6 demographic
questions, to assess representativeness.
We distributed the survey, using Survey Monkey, to a
random sample of members of the Canadian Society of
Nephrology. We chose to survey one-third, rather thanFigure 1 Respondent demographic factors.the whole membership to reduce respondent burden and
maximize the response rate. The identical survey was sent
three separate times within 6 weeks, at 2 week intervals.
Only one response per respondent was permitted.
Fisher’s exact test was used to establish P values be-
tween survey response groups. Ethics approval was re-
ceived by the University of Western Ontario, Health
Sciences Research Ethics Board, Research Ethics Board
number 17036E).
Results
A random selection of every third nephrologist member of
the Canadian Society of Nephrology was sampled (n = 90),
and 56 responded (62%), all of whom were responsible for
the clinical care of patients on hemodialysis (Figure 1).
The majority of respondents practiced in Ontario (54.4%)
or Quebec (15.8%), in keeping with the large population
bases of these two provinces, where 62.0% of Canada’s
population resides [23]. Most had more than 11 years ex-
perience. Most respondents worked in university affiliated
practices (67.8%), the remainder in the community, and
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funded health care system.
Responses to each of 6 cases are shown (Table 1). When
a patient was placed on hemodialysis, uncertainty to con-
tinue warfarin to treat atrial fibrillation increased (from 16
to 36%, P = 0.0300), and the likelihood of starting warfarin
decreased (from 80 to 50%, P = 0.0013). Likelihood of war-
farin use increased as CHADS2 and CHA2DS2VASc score
increased from 2 to 5 (from 50 to 77%, P = 0.0057), so long
at bleeding risks were absent, and though explicit uncer-
tainty was reduced at the higher scores (36% falling to
20%, P = 0.0902), significant uncertainty persisted. Half the
respondents were uncertain when evaluating a scenario in
which the patient was at risk for falls, (Case 4, 48%),
even when there was a high stroke risk (CHADS2 = 5,
CHA2DS2VASc = 8). Nephrologists were more likely to
continue warfarin if there was a history of gastrointes-
tinal bleeding, as opposed to a risk for falls (23% com-
pared with 48%, P = 0.0099), although there was explicit
uncertainty (48%, and 43%, respectively). Very few Ne-
phrologists were likely to prescribe warfarin when a
high stroke risk (CHADS2 = 5, CHA2DS2VASc = 8) was
found with a history of gastrointestinal bleed and risk
for falls (3.6%), while most were unlikely to continue
warfarin (68%); these scenarios highlighted the differ-
ence between new prescription and discontinuation of
an established therapy (3.6% prescribing if not taking v
32% continuing if already taking, P = 0.0001). Even in
this high-risk scenario, with substantial agreement
among nephrologists not to give a new warfarin pre-
scription, explicit uncertainty about the decision was
reported by 29% of nephrologists.
Respondents were asked four questions at the com-
pletion of the initial survey about their feeling of clinical
equipoise, willingness to enter their own patients into a
randomized controlled trial and their feeling that an
RCT would be useful in hemodialysis patients with
atrial fibrillation (Figure 2). The majority (72%) mildly
or strongly agreed that there was a state of genuine
uncertainty within the expert medical community re-
garding the use of oral anticoagulation in hemodialysis
patients with atrial fibrillation. The majority of re-
sponders mildly or strongly agreed that they wouldTable 1 Nephrologist responses, depending on stroke and fal
Case CHADS2 CHADS-Vasc Hemodialysis GI bleed
1 2 3 No No
2 2 3 Yes No
3 5 6 Yes No
4 5 8 Yes No
5 5 8 Yes Yes
6 5 8 Yes Yesenroll patients on hemodialysis with atrial fibrillation into
a randomized control trial, whether the patient is (67%) or
is not (82%) currently anticoagulated. Finally, the over-
whelming majority (98%) would mildly or strongly agree
that the results of a valid and well-conducted RCT on the
use of oral anticoagulation in hemodialysis patients with
atrial fibrillation would inform their practice.
Discussion
Our national survey of the standardized cases revealed
that using warfarin in a patient on hemodialysis versus a
patient with normal renal function increased Nephrologist
uncertainty (Figure 1). CHADS2 and CHA2DS2VASc var-
iables unanimously increased the likelihood of prescribing
warfarin. However, in the second scenario where the pa-
tient had a very high risk for stroke and increased bleeding
risks, there was much more variability and Nephrologist
uncertainty. Previous gastrointestinal bleed was perceived
as lower risk than a patient at risk for falls. As with real
patients, Nephrologist ambiguity for warfarin use in-
creased in patients with several comorbidities. There was
not always a rationale for physician responses and the re-
sponses showed variable physician practices.
We found that asking physicians about their uncer-
tainty directly was most revealing. An overwhelming
majority (98.2%) of Nephrologists agreed that a ran-
domized control trial in this population would inform
their practice (Figure 2). Similarly, a majority of Ne-
phrologists would enroll their own patients in such a
study. Confirming our hypothesis, Nephrologists agreed
(72.2%) that clinical equipoise exists among their com-
munity and that a randomized control trial on this topic
is needed.
Risk thresholds are a critical component in physician
decision-making [24] For example, a decision to anti-
coagulate a patient with atrial fibrillation must weigh
the perceived risks of bleeding and stroke. However,
physicians are historically inaccurate in predicting the
risks in individual patients in a number of clinical con-
texts, even when the probabilities of specific outcomes
are well defined [25-28]. Furthermore, an accurate as-
sessment of risk requires reliable data on outcomes in








No 80.4 3.6 16.1
No 50.0 14.3 35.7
No 76.7 3.6 19.6
Yes 23.2 28.6 48.2
No 48.2 8.9 42.9
Yes 3.6 67.9 28.6
Figure 2 Nephrologist responses to clinical equipoise and willingness to enroll patients in randomized controlled trial.
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elusive in hemodialysis patients with atrial fibrillation.
Certainly this uncertainty can be addressed only with
more definitive data on bleeding, stroke and survival, by
the conduction of well-designed prospective trials.
The anticoagulation of hemodialysis patients with atrial
fibrillation may have unacceptable risks of bleeding [2]. On
the contrary, a high proportion of hemodialysis patients
have atrial fibrillation, [3,4] and the risk of CVA may or
may not be decreased with warfarin use [5,6]. Certainly
there would be a substantial health cost savings due to
elimination of resources dedicated to monitoring, dosing
and prescription of warfarin anticoagulation. However, nei-
ther KDOQI nor KDIGO offer recommendations related to
chronic anticoagulation of hemodialysis patients. Equipoise
reflected in this current study suggests that prospective tri-
als of the two basic strategies (anticoagulation free versus
warfarin anticoagulation), would infer the nephrology litera-
ture with better clinical practice guidelines.There would be clear challenges in funding, designing
and carrying out a randomized controlled trial on warfarin
use in hemodialysis. Since warfarin is inexpensive, readily
available and bioequivalent [29], the funding for such a trial
would need to come from public, rather than pharmaceut-
ical company funding. Alternatively, a newer non-Vitamin
K dependent anticoagulant could be evaluated against war-
farin. However, such a study would be challenging in the
absence of a placebo patient group, since the question of
whether any anticoagulation of any kind is required in this
setting would remain unanswered [30]. Furthermore, there
is limited experience and safety of newer anticoagulants in
hemodialysis patients [31]. Thus, a country with sufficient
public funds would need to initiate this rigorously de-
signed, randomized controlled trial.
Designing a randomized controlled trial in this clinical
setting would need to overcome ethical challenges. Spe-
cifically, randomizing patients to the use of warfarin in
hemodialysis patients may be unethical if clinicians
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Patients may have strong preferences that limit recruit-
ment and bias outcomes [32]. However, this study confirms
that uncertainty is common in Canadian nephrologists,
and that willingness to enter patients into a randomized
trial is high. Thus, it would not be unethical for Canadian
nephrologists to enter their patients into such a trial, since
they don’t feel that anticoagulation of hemodialysis patients
with atrial fibrillation is either inferior or superior. Ultim-
ately, randomized controlled trials are the most rigorous
way of determining whether a cause-effect relation exists
between treatment and outcome [33], and even despite the
above challenges, remains the ideal way to assess the effect
of anticoagulation of hemodialysis patients with atrial
fibrillation.
There are a number of limitations in our study. Firstly,
the survey to the Canadian Society of Nephrologists was
limited in that this survey was a novel tool that has not yet
been validated. The response rate was limited, however the
results still likely reflect the Canadian population of Ne-
phrologists as the demographics of the respondents were
fairly representative of our Nephrology population base
(Figure 1). Secondly, newer novel oral anticoagulants were
not considered in our survey. However, while data on war-
farin use in hemodialysis patients is limited, data on novel
oral anticoagulant use is nonexistent; thus, warfarin is likely
to remain the standard of care in this clinical setting for the
foreseeable future. Finally, the generalizability of these re-
sults is limited as only Canadians were surveyed. Response
bias must also be accounted for when interpreting the re-
sults of the survey.
Conclusions
The results of this study have confirmed that there is lim-
ited evidence in the literature to guide decisions on oral
anticoagulation in hemodialysis patients with atrial fibrilla-
tion. This is reflected in the inconsistent practice among
Nephrologists nationally. The paucity of evidence in the
literature, and the uncertainty in national practice, lend
credence to the performing of a randomized control trial.
Indeed, Canadian Nephrologists agree there is clinical
equipoise, and are willing to enroll their patients in a well
designed randomized control trial.
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